Investors

Five things for pharma marketers to know: Tuesday, December 5, 2017

Five things for pharma marketers to know: Tuesday, December 5, 2017

By

Botox-like wrinkle-reducer shows positive results in trials; investors double down on fertility; few websites transparent about pricing, study finds

Five things for pharma marketers to know: Tuesday, October 31, 2017

Five things for pharma marketers to know: Tuesday, October 31, 2017

By

Pfizer Q3 revenue driven by Prevnar sales; President Trump's opioid panel presents draft to combat crisis; Novartis seeks FDA approval for CAR-T therapy Kymriah

Five things for pharma marketers to know: Monday, June 19, 2017

Five things for pharma marketers to know: Monday, June 19, 2017

By

Adamis receives FDA approval for EpiPen rival Symjepi; Clovis reports positive trial results for ovarian cancer drug Rubraca; hedge fund billionaire John Paulson joins Valeant board of directors

Five things for pharma marketers to know: Thursday, June 15, 2017

Five things for pharma marketers to know: Thursday, June 15, 2017

By

Google invests in European biotechs; hospitals that restrict sales-rep visits more likely to prescribe cheaper generics; AI could help doctors with new research

Five things for pharma marketers to know: Tuesday, March 14, 2017

Five things for pharma marketers to know: Tuesday, March 14, 2017

By

Pershing Square sells entire Valeant stake; FDA approves Novartis breast-cancer drug combo; Express Scripts asks Gilead to lower hep-C drug prices

Five things for pharma marketers to know: Wednesday, January 18, 2017

Five things for pharma marketers to know: Wednesday, January 18, 2017

By

Rep. Price to answer questions at confirmation hearing; 22 drugmakers invest in fighting disease in poor countries; FDA approves generic of Jazz's Xyrem

Five things for pharma marketers to know: Thursday, December 15, 2016

Five things for pharma marketers to know: Thursday, December 15, 2016

By

Drugmakers promote new type of opioid with unproven results; Heritage execs charged for price-fixing generics; Pershing sells more Valeant shares

Five things for pharma marketers to know: Monday, September 26, 2016

Five things for pharma marketers to know: Monday, September 26, 2016

By

Pfizer drops plans to split into two companies; Merck's Keytruda gains competitive edge in China; Apple may be developing health software

Editor's Desk: Escaping the Shkreli Cycle

Editor's Desk: Escaping the Shkreli Cycle

By

Three suggestions for defusing the highly charged pricing atmosphere

Five things for pharma marketers to know: Monday, June 15

Five things for pharma marketers to know: Monday, June 15

By

CVS Health to buy Target's pharmacy business; experimental gene therapy improves condition of teen with sickle-cell disease; PatientsLikeMe partners with the FDA to improve postmarket surveillance